Close
Close

AH10-7

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

AH10-7 incorporates a C6″ hydrocinnamoyl ester and lacks the C4′-OH of the sphingoid base. Using a combination of in vitro studies and in vivo analysis with wild-type and partially humanized mice, it was found that the dual modifications in AH10-7 led to preservation of substantial potency in both mouse and human models of iNKT cell activation while maintaining the Th1-biasing property of other sphinganine derivatives. Structural studies by X-ray crystallography and in silico modeling provided a mechanistic basis for the effect of the C6″ substitution on enhancing presentation of AH10-7 by human CD1d. These results, along with another recently published study of combining C6″ substitutions with other Th1-biasing modifications, provide a rare example of two separate glycolipid modifications that synergize to create an analog of KRN7000 with potentially useful properties, suggesting a new approach to rational design of iNKT cell T cell receptor (TCR) ligands.

  • TCR Vector Products

  • TCR Cell Products

  • TCR Viral Particles

Loading...
  • TCR Clone:
  • Host Species:
  • Epitope:
  • Allele:
  • Vector Type:
CAT Product Name Target Species TCR Clone Host Species Epitope Allele Vector Type Inquiry & Datasheet
TCR-YC0067 Mouse anti-AH10-7 T cell receptor (2C12), pCDTCR1 2C12 Mouse (2S,3R)-1-O-(6-Hydrocinnamoyl-α-D-galactopyranosyl)-2-(N-hexacosanoylamino)octadecane-1,3-diol mouse CD1d Lentiviral vector   Add to Cart   Datasheet
Unable to find the desired product? Explore the Filter Options at the top of the list.
Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.
Copyright © 2024 Creative Biolabs. All Rights Reserved
Cart
    Go to checkout